Skip to main content
Fig. 1 | Cardio-Oncology

Fig. 1

From: 14,15-Dihydroxyeicosatrienoic acid, a soluble epoxide hydrolase metabolite in blood, is a predictor of anthracycline-induced cardiotoxicity – a hypothesis generating study

Fig. 1

Experimental design of early blood biomarker study for doxorubicin (DOX)-induced cardiotoxicity. The experiments are planned for in-vitro and in-vivo in rodents and breast cancer patients. A In-vitro verification of early and diagnosis biomarkers of doxorubicin (DOX)-induced cardiotoxicity, 14,15-DHET, using culture media obtained from H9c2 rat cardiomyocytes. B Confirmation of the in-vitro results using female rates treated with DOX (3 mg/kg). C Breast cancer human plasma analyses prior and after DOX treatment. Cardiotoxicity is defined as an asymptomatic reduction of LVEF of ≥ 10% to < 55% [9]

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us